On 11 Dec 2023, The clinical data about Axicabtagene Ciloleucel from pivotal ZUMA-7 study will be updated in 2023 ASH.

On 11 Dec 2023, the final phase III APPLY-PNH trial data after a 24-wk extension period in which all pts received iptacopan monotherapy will be reported in 2023 ASH.

The latest clinical findings of Revumenib will be unveiled at the 2023 ASH Congress, demonstrating its potential effect and setting the stage for subsequent investigations.

On 11 Dec 2023, the latest clinical trial of Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas will be reported in 2023 ASH.

On 14 Apr 2023, data from first-in-human study of EXS21546, an A2A receptor antagonist, was reported at the AACR Congress.

The initial results from LOXO-RAS-20001, a phase 1 study of LY3537982 in patients (pts) with KRAS G12C-mutant advanced solid tumors were reported at the AACR Congress.

On 11 Dec 2023, the updated clinical results of Axatilimab at 3 different doses in patients with Chronic Graft-Versus-Host Disease (AGAVE-201) will be reported in 2023 ASH.

The latest clinical findings of KT-333 will be unveiled at the 2023 ASH Congress, setting the stage for subsequent investigations.

The 2023 SITC Congress reported that TILT-123, a T-cell inducing oncolytic virus, is safe, effective at fighting tumors, and can boost immune responses in patients with advanced solid tumors.

The latest clinical result of SNS-101(Sensei Biotherapeutics) in patients with advanced solid tumors was reported at the 2023 SITC Congress, demenstrating its potential efficacy and paving the way for future research.

The 2023 SITC Congress kicked off with a groundbreaking report on the latest clinical results of ENB-003, establishing a solid foundation for future research.

On Oct 31, 2023, the latest clinical data of MDNA11 monotherapy in a phase 1/2 study on advanced solid tumors was reported at SITC Congress, showing potential efficacy for future research.